Article
Effect of felzartamab anti-CD38 treatment on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.
2024-08-16
Abstract excerpt
<title>Abstract</title> <p>A recent randomized controlled trial demonstrated that treatment with CD38 monoclonal antibody felzartamab suppressed antibody-mediated rejection (ABMR) in kidney transplant patients but with recurrence post-treatment in some patients. The present study examined the molecular effects of 6-months of felzartamab treatment on biopsies from the trial using genome-wide microarray analysis, c...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 04a935e6-69a1-5c50-ba6e-ee3b0a0a2c95
- DOI
- 10.21203/rs.3.rs-4870641/v1
